ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharmaceuticals has demonstrated robust growth in its core franchises, with Daybue achieving $110 million in sales for the fourth quarter, exceeding consensus estimates and showcasing 13% year-over-year growth. The company is confident in its fiscal year 2026 revenue guidance for Daybue, which predicts $460 million to $490 million, signaling potential upside compared to prior estimates. Furthermore, with a projected $1.7 billion in combined net sales by 2028 and strong prescription growth from both Nuplazid and Daybue, Acadia's core business remains exceptionally strong, supported by recent intellectual property wins that could safeguard Nuplazid's revenue well into the next decade.

The analysis indicates several significant risks affecting ACADIA Pharmaceuticals's stock outlook, primarily related to the company's ability to gain regulatory approval and demonstrate efficacy for additional indications. Challenges include the negative trend vote from the CHMP regarding trofinetide, which may impede its launch in the EU and contribute to uncertainties surrounding the commercial potential for DAYBUE, despite its orphan drug designation. Furthermore, concerns about intellectual property, reimbursement issues, potential slowing uptake of key products like NUPLAZID and DAYBUE, and high dropout rates in clinical studies raise doubts about maintaining growth and financial stability.